About Applied BioCode
Applied BioCode is a company based in Santa Fe Springs (United States) founded in 2008. Applied BioCode has raised $20.29 million across 6 funding rounds from investors including NIH and HHS. Applied BioCode offers products and services including BioCodeĀ® MDx-3000, Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, BioCodeĀ® SARS-CoV-2 Assay, and BioCodeĀ® STI + Resistance Panel. Applied BioCode operates in a competitive market with competitors including Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.
- Headquarter Santa Fe Springs, United States
- Stage Public
- SectorsHealthcare
- Website apbiocode.com
- Social LinkedIn Facebook Instagram YouTube
- Legal Name Applied Biocode Corp.
- Annual Revenue$475.2 M38.52as on Dec 31, 2025
- Net Profit-$201.2 M22.85as on Dec 31, 2025
- EBITDA-$166.96 M22.89as on Dec 31, 2025
- Total Equity Funding$20.29M (USD)
in 6 rounds
- Latest Funding Round$9.26M (USD), Series A
Apr 2016
- InvestorsNIH
& 1 more
Products & Services of Applied BioCode
Applied BioCode offers a comprehensive portfolio of products and services, including BioCode® MDx-3000, Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, BioCode® SARS-CoV-2 Assay, and BioCode® STI + Resistance Panel.
High-throughput system for multiplex pathogen testing
Detects pathogens for gastroenteritis in clinical settings
Identifies common respiratory infection causes
Enables pooled testing for COVID-19 detection
Detects sexually transmitted infections and resistance
Apps and channels of Applied BioCode
its YouTube channel Applied BioCode Inc. has 33.4K subscribers and 18 videos.
Videos from Applied BioCode
The most watched videos on Applied BioCode's YouTube channel, Applied BioCode Inc. (33.4K subscribers). Click a video to play it here.
More on Applied BioCode Inc..
Funding Insights of Applied BioCode
Applied BioCode has successfully raised a total of $20.29M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $9.26 million completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.29M
- Total Rounds 6
- Last Round Series A ā $9.26M
- First Round $2.8M
(Jul 2010)
- Investors Count 2
All 6 funding rounds of Applied BioCode with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Applied BioCode
Applied BioCode has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for Applied BioCode
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Applied BioCode
15 people are tracked at Applied BioCode (6 in leadership, 9 in team).
| Name | Role | Group |
|---|---|---|
Jim Leigh | VP of Sales | Leadership |
Jaca Liang-Kai Huang | CFO | Leadership |
Parisa Hanachi | VP of Marketing | Leadership |
Michael Aye | Chief Scientific Officer | Leadership |
Winston Z. Ho | Founder & CTO | Leadership |
Jerry Kowalski | VP, Operations | Leadership |
Matthew Pardilla | Regional Sales Manager - West Region | Team |
Mayra Garcia | Staff Manager | Team |
Jesse Fisher | Technical Service Manger | Team |
Steven Centeno | Software Engineer | Team |
peter zal | Engineering Technician | Team |
Chia-Hsing Lu | Deputy Manager, HR & Corporate Compliance | Team |
Roger Wang | Scientist I | Team |
Sarah Parker | Senior Medical Sales Representative | Team |
Khai Trinh | Junior Software Engineer | Team |
Complete people profiles for Applied BioCode
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Applied BioCode
Applied BioCode is a publicly listed company on the TWSE with ticker symbol 6598 in Taiwan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Jun 2020
- Listed onTPE: 6598
- Listed entityApplied BioCode Corp.
- Exchange sectorHealth technology
- ISINKYG0488D1051
- Share price27.60 TWD (+3.18% on the day) · 2026-10-08
- Market capitalisation2,837,806,131.00 TWD
- EPS (diluted, trailing year)-0.48 TWD
- Volume (last session)503,552
Financials of Applied BioCode
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 475.2M TWD | -201.2M TWD | -167.0M TWD |
| 2024 | 343.1M TWD | -260.8M TWD | -216.5M TWD |
| 2023 | 395.2M TWD | -164.2M TWD | -124.0M TWD |
| 2022 | 390.3M TWD | -184.7M TWD | -136.1M TWD |
| 2021 | 320.0M TWD | -165.2M TWD | -114.0M TWD |
Detailed financial statements for Applied BioCode
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Applied BioCode
4 dated milestones of Applied BioCode across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Applied BioCode is founded.
- Funding First funding round of $2.8M.
- Funding Latest funding round, Series A, of $9.3M.
- IPO Lists on the stock exchange (IPO).
Competitors of Applied BioCode
Applied BioCode operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. | |
| biocare.net | 1997 | Concord, United States | $85M | 161 | Primary antibodies and instruments for immunohistochemistry are manufactured. | |
| merckgroup.com | 1668 | Darmstadt, Germany | – | 922 | Merck is engaged in science and technology solutions globally. | |
| biolifesolutions.com | 1987 | Bothell, United States | – | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | |
| telesisbio.com | 2013 | San Diego, United States | $25M | – | Online platform offering life sciences reagents and kits | |
| bio-rad.com | 1952 | Hercules, United States | – | 10 | Portfolio of products and services for life science research and clinical diagnostic markets | |
| siemens-healthineers.com | 1847 | Erlangen, Germany | – | 66,000 | AI-based medical diagnostics are developed for healthcare applications. |
Detailed competitors of Applied BioCode
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Applied BioCode
The website of Applied BioCode (apbiocode.com) receives about 8.3K visits a month.
- Monthly visits8.3K
▼ 23.4% vs previous month
Websites whose visitors overlap most with Applied BioCode. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hftforschools.org | hftforschools.org | 100% | – | #3,586,945 | ā |
| hatchspaces.com | 89% | – | #15,018,527 | View details |
Latest news on Applied Biocode
Complete news archive for Applied BioCode
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Applied BioCode
10 companies that operate in the same segment as Applied BioCode (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track ā from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Applied BioCode
Applied BioCode was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Applied BioCode is headquartered in Santa Fe Springs, United States. It is registered at Santa Fe Springs, California, United States.
Applied BioCode is a funded company, having raised a total of $20.29M across 6 funding rounds to date. The company's 1st funding round was a Seed of $2.8M, raised on Jul 2010.
Developer of assay testing kits and instruments for in vitro diagnostics, research, and other industrial applications. The company develops, manufactures, and commercializes multiplex diagnostic testing products that inlcudes testing assays that detect pathogens for gastrointestinal infections, respiratory infections, and other high-value diseases. Also, it offers a BioCode MDx-3000 system with a 17-plex Gastrointestinal Pathogen Panel (GPP) and a 17-plex Respiratory Pathogen Panel (RPP).
Applied BioCode's top competitors include Biocare Medical, Merck and Siemens Healthineers.
Applied BioCode offers BioCodeĀ® MDx-3000, Gastrointestinal Pathogen Panel, Respiratory Pathogen Panel, BioCodeĀ® SARS-CoV-2 Assay, and BioCodeĀ® STI + Resistance Panel.
Yes, Applied BioCode is publicly traded on TWSE under the ticker symbol 6598.
Applied BioCode operates through Applied Biocode Inc.